• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

March 9, 2017

View Archived Issues

U.S. Senate remains committed to $2B NIH budget boost

The U.S. federal budget blues are not going anywhere anytime soon, but Sen. Roy Blunt, chairman of a Senate Appropriations subcommittee, said in a March 8 hearing that Senate appropriators are committed to a $2 billion annual increase in the NIH budget, which would combine with other recent increases to boost NIH funding by more than $44 billion over the coming decade. Read More

Spero pads syndicate, lands $51.7M series C for pipeline of antibacterials

Spero Therapeutics LLC completed a $51.7 million series C preferred financing led by new investor GV (formerly Google Ventures) with the participation of additional new investors RA Capital Management and Rock Springs Capital as well as existing investors, including Atlas Venture, S.R. One Ltd., MRL Ventures Fund, Lundbeckfonden Ventures, the Kraft Group and Osage University Partners. Read More

Ocera can you see? Flag path forward in HE with rifaximin factored in

Ocera Therapeutics Inc. CEO Linda Grais told BioWorld Today that a closer look at data from the failed-but-validating phase IIb STOP-HE study with intravenous (I.V.) OCR-002 (ornithine phenylacetate) gives the company "the basis for an argument that [ammonia levels] should at least be part of a potentially composite endpoint, but we do expect we would still need a clinical component as well" in the next experiments with the compound, in the works for hospitalized patients with hepatic encephalopathy (HE). Read More

Pari Pharma spinout Breath raises $46M A round for lung transplant drug-device combo

DUBLIN – Breath Therapeutics Holding BV raised €43.5 million (US$46 million) in a series A round – Europe's largest so far this year – to undertake phase III trials of a drug-device combo, comprising a nebulizer-delivered, liposome-based formulation of cyclosporine A, in lung transplant patients with bronchiolitis obliterans syndrome (BOS), a chronic progressive airway inflammation that has a major impact on survival rates. Read More

Taiwan's biopharma sector needs stronger commercial focus to thrive

TAIPEI, Taiwan – The government here, despite its good intentions, needs to make changes in its approach to the biopharma industry quickly, said speakers on the first day of the Biologics World Taiwan 2017 conference. Read More

Sanofi Genzyme steps in to fill gap left by New Zealand's failure to pay for rare disease drugs

PERTH, Australia – More patients with Pompe disease in New Zealand will now have access to Sanofi Genzyme's enzyme replacement therapy Myozyme (alglucosidase alfa), but not because the country's single payer will pay for the drug. Rather, Sanofi Genzyme, of Cambridge, Mass., part of Sanofi SA, has stepped in to provide the therapy for free to patients in New Zealand. Read More

Financings

Beyondspring Pharmaceuticals Inc., of New York, which is developing an immuno-oncology agent plinabulin, in a phase III trial for the reduction of docetaxel-induced neutropenia, has amended its IPO filing to now raise up to $3 million by offering 143,000 shares in the price range of $20 to $22. Read More

Other news to note

Allergan plc, of Dublin, said the FDA accepted for filing its supplemental NDA for Vraylar (cariprazine), seeking the addition of new clinical data evaluating the drug for the maintenance of efficacy in adults with schizophrenia to the current product label. Read More

In the clinic

Menlo Therapeutics Inc., of Menlo Park, Calif., said a phase II trial (TCP-102) evaluating serlopitant to treat pruritus (itch) associated with prurigo nodularis met its primary efficacy endpoint and key secondary endpoints, demonstrating a statistically significant reduction in pruritus (p Read More

Regulatory front

Morton Grove Pharmaceuticals Inc., a subsidiary of Mumbai, India-based Wockhardt Ltd., received an FDA warning letter stemming from an inspection conducted more than a year ago at the Illinois facility. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 11, 2025.
  • AI-generated illustration of heart and metabolic impact

    Deep Apple signs big Novo deal for cardiometabolic small molecules

    BioWorld
    Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
  • DNA double helix under a magnifying glass

    23andme genetic privacy concerns garner Congressional scrutiny

    BioWorld MedTech
    The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...
  • Red and blue bispecific antibodies

    3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

    BioWorld
    3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe